2022
SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA
de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P, O'Brien B, Sloan A, Chiang V, Tatter S, Mohammadi A, Placantonakis D, Strowd R, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope K, Campian J, Kurz S, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt E. SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA. Neuro-Oncology 2022, 24: vii256-vii257. PMCID: PMC9660753, DOI: 10.1093/neuonc/noac209.989.Peer-Reviewed Original ResearchLaser interstitial thermal therapyIDH wild-type glioblastomaConventional surgical resectionWild-type glioblastomaInterstitial thermal therapySurgical resectionProspective multicenter registryMaximal safe resectionTime of diagnosisGross total resectionPrimary brain tumorsCytoreductive approachMedian OSAdjuvant temozolomideHospital stayMulticenter registryAdverse eventsOverall survivalRecurrent patientsClinical outcomesRecurrent GBMTraditional resectionMedian lengthSurgical approachTreatment optionsEfficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.Peer-Reviewed Original ResearchMedian overall survivalLaser interstitial thermal therapyOverall survivalRecurrent patientsWild-type glioblastomaRecurrent glioblastomaGlioblastoma patientsProspective multicenter registry dataMulticenter registry dataRecurrent glioblastoma patientsChemo/radiationPrimary brain tumorsInterstitial thermal therapyIDH wild-type glioblastomaAdjuvant chemotherapyAdverse eventsImproved survivalClinical outcomesPromoter methylation statusMultivariable differenceSurgical approachTreatment optionsRegistry dataUS CentersTumor volume
2021
Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report
Lu BY, Isitan C, Mahajan A, Chiang V, Huttner A, Mitzner JR, Wesley SF, Goldberg SB. Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report. JTO Clinical And Research Reports 2021, 2: 100183. PMID: 34590030, PMCID: PMC8474265, DOI: 10.1016/j.jtocrr.2021.100183.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMultiple sclerosisRadiation necrosisBrain lesionsWhole-brain radiation therapyImmune checkpoint therapyViable tumor cellsPaucity of dataBrain metastasesCheckpoint inhibitorsMetastatic NSCLCAdverse eventsCheckpoint therapyDurable responsesNeurologic declineRadiographic benefitIntracranial complicationsPathologic findingsAutoimmune disordersAutoimmune diseasesCase reportIntracranial diseaseRadiation therapyStereotactic radiosurgeryAnticancer benefits
2020
A prospective multicenter study of laser ablation for drug resistant epilepsy – One year outcomes
Landazuri P, Shih J, Leuthardt E, Ben-Haim S, Neimat J, Tovar-Spinoza Z, Chiang V, Spencer D, Sun D, Fecci P, Baumgartner J. A prospective multicenter study of laser ablation for drug resistant epilepsy – One year outcomes. Epilepsy Research 2020, 167: 106473. PMID: 33045664, DOI: 10.1016/j.eplepsyres.2020.106473.Peer-Reviewed Original ResearchConceptsMesial temporal lobe epilepsyLaser interstitial thermal therapySeizure outcomeLife scoresPotential clinical characteristicsMulti-center registryDrug-resistant epilepsyProspective multicenter studyEffective treatment optionTemporal lobe epilepsyFocal cortical dysplasiaSocial functioning scoresInterstitial thermal therapyEngel IPain scoresAdverse eventsClinical characteristicsSeizure worryEpilepsy typeResistant epilepsySurgical treatmentShorter hospitalizationCortical dysplasiaHypothalamic hamartomaLobe epilepsyLaser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery 2020, 87: e338-e346. PMID: 32315434, PMCID: PMC7534487, DOI: 10.1093/neuros/nyaa071.Peer-Reviewed Original ResearchConceptsKarnofsky performance scorePrimary tumorBaseline Karnofsky performance scoreCancer Therapy-BrainPostprocedure hospital stayReal-world registryPatient-reported QOLNeurological tissuesHigh-grade gliomasQuality of lifeReal-world outcomesBaseline comorbiditiesHospital stayAdverse eventsMost patientsOverall survivalMedian ageBrain tumor ablationRadiation necrosisPatient populationMetastatic cancerFunctional assessmentSurvival rateBaseline levelsQoLPembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2019
Complications associated with immunotherapy for brain metastases.
Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/wco.0000000000000756.Peer-Reviewed Original ResearchConceptsBrain metastasesNeurologic toxicityImmune therapyPhase 2 clinical trialCheckpoint inhibitor therapyImmune checkpoint inhibitorsMultiple phase 2 clinical trialsTreatment-related morbidityBrain metastatic diseaseSymptomatic edemaCheckpoint inhibitorsAdverse eventsDurable responsesMedian survivalMetastatic diseaseInhibitor therapyMore patientsIntracranial activityPatient groupRadiation necrosisClinical trialsTherapy trialsMultidisciplinary teamMetastasisPatients
2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal Of Clinical Oncology 2018, 37: 52-60. PMID: 30407895, PMCID: PMC6354772, DOI: 10.1200/jco.18.00204.Peer-Reviewed Original ResearchConceptsBrain metastasis responseBrain metastasesMetastasis responseAdverse eventsAnti-programmed cell death-1 (PD-1) agentsDeath ligand 1 (PD-L1) expressionModified Response Evaluation CriteriaPhase II clinical trialActive brain metastasesAsymptomatic brain metastasesCD8 cell densityNeurologic adverse eventsPembrolizumab-treated patientsUse of pembrolizumabMelanoma brain metastasesPrimary end pointLigand 1 expressionPhase II trialResponse Evaluation CriteriaT-cell infiltratesUntreated brain metastasesDeath ligand 1Two-year survivalOverall survival timeResult of progressionSURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY
Kamath A, Tatter S, Fecci P, Chen C, Chiang V, Rao G, Mohammadi A, Judy K, Field M, Neimat J, Leuthardt E, Kim A. SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY. Neuro-Oncology 2018, 20: vi251-vi251. PMCID: PMC6216263, DOI: 10.1093/neuonc/noy148.1042.Peer-Reviewed Original ResearchLaser interstitial thermal therapyBrain metastasesProcedural dataDeath rateAblation coverageMedian overall survivalAcceptable safety profileSingle-center experienceDay of procedureKaplan-Meier survivalNeurological tissuesAverage lesion volumeLocation of lesionsPreliminary outcomesInterstitial thermal therapyAdverse eventsOngoing registryOverall survivalCenter experienceSafety profileMean ageInvasive optionTarget lesionsProcedural efficacyLesion volume
2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/s1470-2045(16)30053-5.Peer-Reviewed Original ResearchConceptsProgressive brain metastasesUntreated brain metastasesBrain metastasis responseYale Cancer CenterBrain metastasesPhase 2 trialCell lung cancerAdverse eventsMetastasis responseCancer CenterLung cancerMelanoma cohortGrade 3 colitisGrade 3 fatigueGrade 3 pneumonitisPD-1 axisAcute kidney injuryNeurological adverse eventsPD-1 inhibitorsAcceptable safety profilePD-L1 expressionSystemic immunotherapyKidney injuryPrimary endpointNSCLC cohort
2013
Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases
Husain ZA, Thibault I, Letourneau D, Ma L, Keller H, Suh J, Chiang V, Chang EL, Rampersaud RK, Perry J, Larson DA, Sahgal A. Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases. CNS Oncology 2013, 2: 259-270. PMID: 25054466, PMCID: PMC6166530, DOI: 10.2217/cns.13.11.Peer-Reviewed Original ResearchConceptsSpine stereotactic body radiotherapyStereotactic body radiotherapyBody radiotherapySpinal metastasesMajor serious adverse eventsRole of surgerySerious adverse eventsConventional palliative radiotherapyPain controlPalliative radiotherapyAdverse eventsClinical outcomesConventional radiotherapyRadiotherapyEffective dosesMetastasisPatientsSurgeryTumorsDoses